Literature DB >> 20382692

The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84).

Katherine Wesseling-Perry1, G Chris Harkins, He-jing Wang, Robert Elashoff, Barbara Gales, Mara J Horwitz, Andrew F Stewart, Harald Jüppner, Isidro B Salusky.   

Abstract

CONTEXT: Factors contributing to PTH resistance in dialysis patients remain elusive.
OBJECTIVES: The study assessed the skeletal and biochemical response to 46 h of PTH(1-34) infusion in dialysis patients.
DESIGN: The study was a prospective, controlled assessment of response to PTH(1-34).
SETTING: The study was performed at the University of California, Los Angeles, General Clinical Research Center. PARTICIPANTS: Nineteen dialysis patients and 17 healthy volunteers were studied. INTERVENTION: PTH(1-34) was infused at a rate of 8 pmol/kg x h for 46 h. Bone biopsy was performed in all dialysis patients. MAIN OUTCOME MEASURES: Serum calcium, phosphorus, 1,25-dihydroxyvitamin D, PTH (four separate assays), and FGF-23 were determined at baseline and h 7, 23, 35, and 46 of the infusion.
RESULTS: Serum calcium levels rose in healthy volunteers (9.2 +/- 0.1 to 11.9 +/- 0.3 mg/dl; P < 0.01) and in dialysis patients with adynamic/normal bone turnover (9.0 +/- 0.3 to 10.7 +/- 0.7 mg/dl; P < 0.05) but did not change in dialysis patients with high bone turnover. Serum phosphorus levels declined in healthy volunteers (3.9 +/- 0.1 to 3.5 +/- 0.1 mg/dl; P < 0.05) but increased in all dialysis patients (6.7 +/- 0.4 to 8.0 +/- 0.3 mg/dl; P < 0.05). Full-length PTH(1-84) declined in all subjects; however, PTH(7-84) fragments declined only in healthy subjects and in dialysis patients with normal/adynamic bone but remained unchanged in dialysis patients with high bone turnover.
CONCLUSIONS: The skeleton of dialysis patients with high bone turnover is resistant to the calcemic actions of PTH. PTH(7-84) may contribute to this phenomenon.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20382692      PMCID: PMC2902063          DOI: 10.1210/jc.2009-1909

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  52 in total

1.  Improved methodology for the analysis of plasma vitamin D metabolites.

Authors:  R L Horst; T A Reinhardt; B W Hollis
Journal:  Kidney Int Suppl       Date:  1990-09       Impact factor: 10.545

2.  Bone disease in children and adolescents undergoing successful renal transplantation.

Authors:  C P Sanchez; I B Salusky; B D Kuizon; J A Ramirez; B Gales; R B Ettenger; W G Goodman
Journal:  Kidney Int       Date:  1998-05       Impact factor: 10.612

3.  Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration.

Authors:  I B Salusky; B D Kuizon; T R Belin; J A Ramirez; B Gales; G V Segre; W G Goodman
Journal:  Kidney Int       Date:  1998-09       Impact factor: 10.612

4.  A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure.

Authors:  M R John; W G Goodman; P Gao; T L Cantor; I B Salusky; H Jüppner
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

5.  Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD.

Authors:  B D Kuizon; W G Goodman; H Jüppner; I Boechat; P Nelson; B Gales; I B Salusky
Journal:  Kidney Int       Date:  1998-01       Impact factor: 10.612

6.  PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uraemic rats.

Authors:  P Ureña; A Ferreira; C Morieux; T Drüeke; M C de Vernejoul
Journal:  Nephrol Dial Transplant       Date:  1996-10       Impact factor: 5.992

7.  Parathyroidectomy does not prevent the renal PTH/PTHrP receptor down-regulation in uremic rats.

Authors:  P Ureña; M Mannstadt; M Hruby; A Ferreira; F Schmitt; C Silve; R Ardaillou; B Lacour; A B Abou-Samra; G V Segre
Journal:  Kidney Int       Date:  1995-06       Impact factor: 10.612

8.  Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women.

Authors:  M Parisien; F Cosman; R W Mellish; M Schnitzer; J Nieves; S J Silverberg; E Shane; D Kimmel; R R Recker; J P Bilezikian
Journal:  J Bone Miner Res       Date:  1995-09       Impact factor: 6.741

9.  Evidence for abnormal calcium homeostasis in patients with adynamic bone disease.

Authors:  P Kurz; M C Monier-Faugere; B Bognar; E Werner; P Roth; J Vlachojannis; H H Malluche
Journal:  Kidney Int       Date:  1994-09       Impact factor: 10.612

10.  Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols.

Authors:  Katherine Wesseling-Perry; G Chris Harkins; He-Jing Wang; Shobha Sahney; Barbara Gales; Robert M Elashoff; Harald Jüppner; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2009-03-20       Impact factor: 3.714

View more
  25 in total

1.  Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.

Authors:  Stuart M Sprague; James B Wetmore; Konstantin Gurevich; Gerald Da Roza; John Buerkert; Maureen Reiner; William Goodman; Kerry Cooper
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-14       Impact factor: 8.237

Review 2.  Sclerostin: a new biomarker of CKD-MBD.

Authors:  Andreja Figurek; Merita Rroji; Goce Spasovski
Journal:  Int Urol Nephrol       Date:  2019-10-14       Impact factor: 2.370

3.  Lack of FGF23 response to acute changes in serum calcium and PTH in humans.

Authors:  Katherine Wesseling-Perry; Hejing Wang; Robert Elashoff; Barbara Gales; Harald Jüppner; Isidro B Salusky
Journal:  J Clin Endocrinol Metab       Date:  2014-07-25       Impact factor: 5.958

4.  (1-34) Parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers.

Authors:  Orlando M Gutiérrez; Kelsey T Smith; Allison Barchi-Chung; Neha M Patel; Tamara Isakova; Myles Wolf
Journal:  Clin J Am Soc Nephrol       Date:  2012-01       Impact factor: 8.237

5.  Early skeletal and biochemical alterations in pediatric chronic kidney disease.

Authors:  Katherine Wesseling-Perry; Renata C Pereira; Chi-Hong Tseng; Robert Elashoff; Joshua J Zaritsky; Ora Yadin; Shobha Sahney; Barbara Gales; Harald Jüppner; Isidro B Salusky
Journal:  Clin J Am Soc Nephrol       Date:  2011-11-03       Impact factor: 8.237

6.  Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study.

Authors:  Orlando M Gutiérrez; Myles Wolf; Eric N Taylor
Journal:  Clin J Am Soc Nephrol       Date:  2011-10-27       Impact factor: 8.237

7.  FGF-23 levels in patients with AKI and risk of adverse outcomes.

Authors:  David E Leaf; Myles Wolf; Sushrut S Waikar; Herbert Chase; Marta Christov; Serge Cremers; Leonard Stern
Journal:  Clin J Am Soc Nephrol       Date:  2012-06-14       Impact factor: 8.237

Review 8.  Bone disease in pediatric chronic kidney disease.

Authors:  Katherine Wesseling-Perry
Journal:  Pediatr Nephrol       Date:  2012-10-14       Impact factor: 3.714

Review 9.  The osteocyte in CKD: new concepts regarding the role of FGF23 in mineral metabolism and systemic complications.

Authors:  Katherine Wesseling-Perry; Harald Jüppner
Journal:  Bone       Date:  2012-10-16       Impact factor: 4.398

10.  Key role of the kidney in the regulation of fibroblast growth factor 23.

Authors:  Maria L Mace; Eva Gravesen; Jacob Hofman-Bang; Klaus Olgaard; Ewa Lewin
Journal:  Kidney Int       Date:  2015-07-29       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.